2024年一季报披露正接近尾声。从已披露情况来看,报告期内,科创板创新药企业合计实现营业收入超110亿元,同比增长超40%;归母净利润近40亿元,同比扭亏为盈,迎来“开门红”。
本文源自金融界AI电报
特别声明:以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布,本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.